Director's Dealing • May 1, 2019
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
RNS Number : 7965X
Mereo BioPharma Group plc
01 May 2019
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director Dealing
London, May 1, 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Darcy Nicolle, a person closely associated (PCA) with Wills Hughes-Wilson, Head of Patient Access, purchased 8000 ordinary shares at a price of GBP1.19 per share.
On 30 April 2019, Charles Sermon, General Counsel of Mereo BioPharma, purchased 6456 American Depositary Shares (ADSs) at a price of USD6.00 per share and Richard Jones, Chief Financial Officer of Mereo BioPharma, purchased 1050 American Depositary Shares (ADSs) at a price of USD6.04 per share.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1
Details of the person discharging managerial responsibilities
a)
Name
Darcy Nicolle
2
Reason for the notification
a)
Position/status
Person closely associated (PCA) with Wills Hughes-Wilson, Head of Patient Access
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mereo BioPharma Group plc
b)
LEI
213800U8JQHIJOS5AS09
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Ordinary Shares
b)
Nature of the transaction
Purchase
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| GBP1.19 | 8000 |
d)
Aggregated information: volume, Price
Aggregated volume: 8000
Aggregated price: GBP1.194
e)
Date of the transaction
2019-04-29
f)
Place of the transaction
AIMX
1
Details of the person discharging managerial responsibilities
a)
Name
Charles Sermon
2
Reason for the notification
a)
Position/status
General Counsel
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mereo BioPharma Group plc
b)
LEI
213800U8JQHIJOS5AS09
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)
b)
Nature of the transaction
PURCHASE
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| USD6.00 | 6456 |
d)
Aggregated information: volume, Price
Aggregated volume: 6456
Aggregated price: USD6.00
e)
Date of the transaction
2019-04-30
f)
Place of the transaction
XNMS
1
Details of the person discharging managerial responsibilities
a)
Name
Richard Jones
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mereo BioPharma Group plc
b)
LEI
213800U8JQHIJOS5AS09
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
ADS
b)
Nature of the transaction
Purchase
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| USD5.94 | 1050 |
d)
Aggregated information: volume, Price
Aggregated volume: 1050
Aggregated price: USD5.94
e)
Date of the transaction
2019-04-30
f)
Place of the transaction
XNMS
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHZFLFBKEFZBBE
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.